Literature DB >> 8353036

Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer.

O Gallo1, A M Gori, M Attanasio, F Martini, B Giusti, M Boddi, E Gallina, O Fini, R Abbate.   

Abstract

In patients with advanced head and neck squamous cell carcinoma (HNSC), evidence of cell-mediated immunity and monocyte functional abnormalities has been reported. We studied the production of interleukin 1 beta (IL-1 beta) and interleukin 6 (IL-6) by peripheral blood monocytes from 22 patients with HNSC (12 larynx and ten oral cavity cancers) in comparison with monocyte cytokine production of age-matched healthy subjects. Pure monocytes were incubated with and without lipopolysaccharides (LPS) (10 micrograms ml-1) for 4 h at 37 degrees C and IL-1 beta and IL-6 concentrations were determined in supernatants by specific ELISA. There was no significant difference in IL-1 beta levels in monocyte supernatants from cancer in comparison to control subjects; conversely, a higher IL-6 production by unstimulated and LPS-activated cells from HNSC patients than from controls was found. No relationship was observed between cytokine production and cancer stage. The regression analysis evidenced a significant correlation between IL-1 beta and IL-6 monocyte-release in HNSC patients and in controls, so suggesting a possible autocrine control of IL-6 production by other cytokines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353036      PMCID: PMC1968396          DOI: 10.1038/bjc.1993.371

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Monocytes and impaired leukocyte migration inhibitory factor production in head and neck squamous carcinoma.

Authors:  M L Beauchamp; G T Wolf
Journal:  Head Neck Surg       Date:  1988 Jan-Feb

2.  Interleukin-1 induces interleukin-6 production in peripheral blood monocytes.

Authors:  G Tosato; K D Jones
Journal:  Blood       Date:  1990-03-15       Impact factor: 22.113

3.  IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans.

Authors:  D M Jablons; J J Mulé; J K McIntosh; P B Sehgal; L T May; C M Huang; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

4.  Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines.

Authors:  Y Morinaga; H Suzuki; F Takatsuki; Y Akiyama; T Taniyama; K Matsushima; K Onozaki
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

5.  IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma.

Authors:  A Erroi; M Sironi; F Chiaffarino; Z G Chen; M Mengozzi; A Mantovani
Journal:  Int J Cancer       Date:  1989-11-15       Impact factor: 7.396

6.  Interleukin-1 and tumor necrosis factor production by tumor-associated mononuclear leukocytes and peripheral mononuclear leukocytes in cancer patients.

Authors:  J S Economou; S D Colquhoun; T M Anderson; W W McBride; S Golub; E C Holmes; D L Morton
Journal:  Int J Cancer       Date:  1988-11-15       Impact factor: 7.396

7.  Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF.

Authors:  R Schindler; J Mancilla; S Endres; R Ghorbani; S C Clark; C A Dinarello
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

8.  Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis.

Authors:  R Jänicke; D N Männel
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

Review 9.  Biology of interleukin 1.

Authors:  C A Dinarello
Journal:  FASEB J       Date:  1988-02       Impact factor: 5.191

10.  The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells.

Authors:  A Muraguchi; T Hirano; B Tang; T Matsuda; Y Horii; K Nakajima; T Kishimoto
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  7 in total

1.  Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer.

Authors:  Ewa Jablonska; Leszek Piotrowski; Zyta Grabowska
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

2.  Health behaviors predict higher interleukin-6 levels among patients newly diagnosed with head and neck squamous cell carcinoma.

Authors:  Sonia A Duffy; Theodoros Teknos; Jeremy M G Taylor; Karen E Fowler; Mozaffarul Islam; Gregory T Wolf; Scott McLean; Tamer A Ghanem; Jeffrey E Terrell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-08       Impact factor: 4.254

3.  Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma.

Authors:  Y Nakano; W Kobayashi; S Sugai; H Kimura; S Yagihashi
Journal:  Jpn J Cancer Res       Date:  1999-08

Review 4.  The Role of Immune Modulatory Cytokines in the Tumor Microenvironments of Head and Neck Squamous Cell Carcinomas.

Authors:  Nobuo Kondoh; Masako Mizuno-Kamiya
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

Review 5.  Mononuclear phagocytes in head and neck squamous cell carcinoma.

Authors:  Kenneth Wilfried Kross; John-Helge Heimdal; Hans Jørgen Aarstad
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-12-05       Impact factor: 2.503

Review 6.  Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis.

Authors:  Bodo E Lippitz; Robert A Harris
Journal:  Oncoimmunology       Date:  2016-05-11       Impact factor: 8.110

7.  Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study.

Authors:  Marta Tenuta; Alain Gelibter; Carla Pandozzi; Grazia Sirgiovanni; Federica Campolo; Mary Anna Venneri; Salvatore Caponnetto; Enrico Cortesi; Paolo Marchetti; Andrea M Isidori; Emilia Sbardella
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.